Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Selumetinib - AstraZeneca

Next Previous
Drug Profile

Selumetinib - AstraZeneca

Alternative Names: AR 00142886; AR 142886 X; ARRY-142886; ARRY-886; AZD 142886; AZD-6244; AZD-6244 hydrogen sulfate; AZD6244 Hyd-Sulfate; AZD6244 hydrogen sulphate; KOSELUGO; MK 5618; NSC-748727; Selumetinib hydrogen sulfate

Latest Information Update: 15 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Array BioPharma
  • Developer Array BioPharma; AstraZeneca; Cancer Research UK; Merck & Co; Merck Sharp & Dohme Corp.; National Cancer Institute (USA); University of Cambridge; University of Chicago
  • Class Amides; Amines; Antineoplastics; Benzimidazoles; Halogenated hydrocarbons; Small molecules
  • Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neurofibromatosis 1; Thyroid cancer; Uveal melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Neurofibromatosis 1
  • Phase III Glioma
  • Phase II Biliary cancer; Colorectal cancer; Gastric cancer; Histiocytosis; Neurofibromatosis 2; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Solid tumours; Uveal melanoma
  • Phase I/II Kaposi's sarcoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase I Myelodysplastic syndromes; Myelofibrosis; Plexiform neurofibroma
  • No development reported Pancreatic cancer
  • Discontinued Acute myeloid leukaemia; Liver cancer; Malignant melanoma; Multiple myeloma; Thyroid cancer

Most Recent Events

  • 14 Feb 2024 AstraZeneca completes a phase I/II clinical trials in Glioma (Inoperable/Unresectable, In children, In adolescents, In adults, Second-line therapy or greater) in United Kingdom (PO, Capsule) (NCT03326388)
  • 14 Feb 2024 AstraZeneca completes a phase I/II clinical trials in Neurofibromatosis 1 (In adolescents, In children, Inoperable/Unresectable, Second-line therapy or greater, In adults) in United Kingdom (PO, Tablet) (NCT03326388)
  • 14 Feb 2024 AstraZeneca completes a phase I/II clinical trials in Plexiform neurofibroma (In adolescents, In children, Inoperable/Unresectable, Second-line therapy or greater, In adults) in United Kingdom (PO, Tablet) (NCT03326388)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top